The gap between research and practice is well documented. We address one of the underlying reasons for this gap: the assumption that effectiveness research naturally and logically follows from successful efficacy research. These 2 research traditions have evolved different methods and values; consequently, there are inherent differences between the characteristics of a successful efficacy intervention versus those of an effectiveness one. Moderating factors that limit robustness across settings, populations, and intervention staff need to be addressed in efficacy studies, as well as in effectiveness trials. Greater attention needs to be paid to documenting intervention reach, adoption, implementation, and maintenance. Recommendations are offered to help close the gap between efficacy and effectiveness research and to guide evaluation and possible adoption of new programs. (Am J
Despite a growing literature documenting prevention and health promotion interventions that have proven successful in well-controlled research, few of these interventions are consistently implemented in applied settings. This is true across preventive counseling services for numerous target behaviors, including tobacco use, dietary change, physical activity, and behavioral heailth issues (e.g., alcohol use, depression). Several recent reviews and metaanalyses have documented this gap,''^ and the task forces on both clinical preventive services and community preventive services have noted that in several areas there is insufSdent appUed evidence available to make recommendations at present ^"^ Most of the Healthy People 2000 objectives^ were not met, and the even more ambitious goals in Healthy People 2010 are similarly unlikely to be met without significant changes in the status quo.^'* To meet these challenges, we will need to have substantially more demonstrations of how to effectively implement recommendations in typical settings and in locations serving minority, low-income, and rural populations facing health disparities.
This situation is not unique to preventive interventions, as strikingly documented in the recent Institute of Medicine report Crossing the Chasm^ which summarizes the similar state of affairs regarding many medical and disease management interventions. For example, there is increasing consensus on evidence-based diabetes management practices to prevent complications and on the importance and costeffectiveness of these practices.'" However, these recommendations-and especially those related to lifestyle counseling and behavioral issues-are poorly implemented in practice."^''* This gap between research and practice is the result of several interacting factors, including limited time and resources of practitioners, insufficient training,'' lack of feedback and incentives for use of evidence-based practices, and inadequate infrastructure and systems organization to support translation.®'Î n this article, we focus on another reason for the slow and incomplete translation of research findings into practice: the logic and assumptions behind the design of efficacy and effectiveness research trials.
EFFICACY AND EFFECTIVENESS TRIALS
Many of the methods used in current prevention science are based on 2 influential papers published in the 1980s: Greenwald and Cullen's'^ description of the phases of cancer control research and Flay's analysis of efficacy and effectiveness research.'^ Both papers argued for a logical progression of research designs through which promising intervention ideas should proceed. These papers had many positive effects in helping to establish prevention research and enhancing acceptability among other disciplines. However, they may also have had an important and inadvertent negative consequence that derives from the assumption that the best candidates for effectiveness studies-and later dissemination-are interventions that prove successful in certain types of efficacy research. We argue that this assumption, or at least the way in which it has been operationalized over the past 15 years, has often led to interventions that have low probability of success in real-world settings.
To understand this point, it is necessary first to briefly review the seminal papers by Flay'â nd Greenwald and Cullen.'^ Efficacy trials are defined by Flay as a test of whether a "program does more good than harm when delivered under optimum conditions."'*''''"" Efficacy trials are characterized by strong control in that a standardized program is delivered in a uniform fashion to a specific, often narrowly defined, homogeneous target audience. Owing to the strict standardization of efficacy trials, any positive (or negative) effect can be directly attributed to the intervention being studied.
Effectiveness trials are defined as a test of whether a "program does more good than harm when delivered under real-wOrld conditions."'*"'"''^" They typically standardize availability and access among a defined population while allowing implementation and levels of participation to vary on the basis of realworld conditions. The primary goal of an effectiveness tried is to detennine whether an intervention works among a broadly defined population. Effectiveness trials that result in no change may be the result of a lack of proper implementation or weak acceptance or adherence by participants.'*'Ĝ reenwald and Cullen'^ proposed 5 phases of intervention research presumed to unfold in ME a sequential fashion. This continuum begins with Phase I research to formtiJate and develop intervention Jiypotheses for future study. Phase II studies develop methodologies that can be used in future efBcacy or effectiveness studies. Phase III (efficacy) studies test intervention hypotheses, using methods that have been tested in Phase Jl. TJius, Phase III studies are designed to test interventions for efBcacy, vnth an emphasis on internal validity, tJie purpose of wJiich is to establish a eausal link between the intervention and outcomes. Given this emphasis on internal control, Greenwald and Cullen note that Phase III studies can be conducted in settings and witb stimples that will "optimize interpretation of efBcacy," including study samples tbat may be more homogeneous tban tbe ultimate target population, and settings tbat will maximize management of and control over tbe researcb process.
Tbe main objective of Phase fV (effectiveness) studies is to measure tbe impact of an intervention when it is tested witbin a population tbat is representative of tbe intended target audienee. Given that Pbase JV studies should yield results tbat are generalizable, there is also tbe presumption tbat tbe context and setting for delivering tbe intervention should likewise be generalizable to tbe intended program users. Jn Pbase V studies, effective Pbase JV interventions are translated into large-scale demonstration projects. Tbe major concern is implementation fidelity of an intervention tbat will now be introduced witbin even broader populations, including entire communities. Tbis final pbase (dissemination researeb), wbere collaboration and coordination witb various community partners is likely to receive even greater attention, is intended to provide tbe necessary data and experience to move interventions into public bealth service programs at tbe national, regional, state, and local levels.
Greenwald and Cullen spedficaUy advocated tbat intervention researcb unfold in a systematic fasbion, building on and extending tbe body of science acctimulated in previous pbases. By explicitly defining tbe difference between Pbase JJJ and Pbase IV researcb as being an empbasis on internal control versus representativeness, botb Flay and Greenwald and CuUen assumed tbat successful Pbase III trials would lead naturally to Pbase fV trials. Unfortunately, tbis bas not ocaured.''"'^" Instead, we currently find ourselves in a situation in wbicb we bave many small-scale efBcacy studies of unJoiown generalizability and few suceessiuJ effectiveness trials.^''^^ In particular, we know very little about tbe representativeness of participants, settings, or intervention agents participating in bealtb promotion research.''^' Altbougb tbe National Gancer Institute no longer empbasizes tJiis linear "pbases of researcb" model,^'''^'' tbe model was extremely influential in guiding an entire generation of researeb; many researcbers, reviewers, and editors still use tbis framework wben designing, ftmding, and evaluating research-and in deciding wbat types of studies are needed to advance a given area. Similar pbase models are influential in evaluating prevention effectiveness^^ and in developing drug therapies. In tbe remainder of tbis article, we discuss bow tbis well-intentioned and logical pbase of researcb paradigm may bave fallen sbort of its intended goal, and propose approacbes to remedy tbe present situation.
Our primary thesis is tbat tbis "triekledown" model of bow to translate researcb into practice-namely, tbat tbe optimal way to develop disseminable interventions is to progress from efBcacy studies to effectiveness trials to dissemination projects-is inherently flawed, or at least incomplete. We posit that given tbe respective cultures, values, and methodological traditions tbat bave developed witbin efBcacy versus population-based effectiveness researcb, it is bigbly unlikely tbat interventions tbat are successful in efBcacy studies will do well in effectiveness studies, or in real-world applications. Table 1 summarizes tbe key cbaracteristics of well-designed efficacy and effectiveness trials, using tbe RE-AIM evaluation framework.^^'^^ Tbis model for evaluating interventions is intended to refoctis priorities on public bealtb issues, and it gives balanced empbasis to internal and external validity (see bttp://www.re-aim.org). RE-AIM is an acronym for Reach, Efficacy or Effectiveness (depending on tbe stage of researcb). Adoption, Implementation, and Maintenance.
Reach refers to tbe participation rate among tbose approacbed and tbe representativeness of participants. Factors determining reaeb are tbe size and cbaracteristics of tbe potential audience and tbe barriers to participation (e.g., cost, sodaJ and environmental context, necessary referrals, transportation, and inconvenience). Efficacy or effectiveness pertains to tbe impact of an intervention on specified outcome criteria and includes measures of potential negative outcomes as well as intended re- cost, level of resources and expertise required, and how similar a proposed service is to current practices of an organization. Implementation refers to intervention integrity, or the quality and consistency of delivery. Finally, maintenance operates at both the individual and the setting or organizational level. At the individual level, maintenance refers to how well hehavior changes hold up in the long term. At the setting level, it refers to the extent to which a treatment or practice becomes institutionalized in an organization. Table 1 summarizes how the RE-AIM dimensions apply to the efiicacy-efTectiveness distinction. Efficacy trials typically limit reach by seeking motivated, homogeneous participants with minimal or no complications or comorbidities. The considerable degree of initial screening for eligibility inherently limits the reach of an eflicacy trial. Adoption is often treated as a nonissue for efficacy trials so long as at least one or, in some tdeds, a few settings are willing to participate. For effectiveness trials, reach is usually higher because participants are drawn from a broad and "defined" population. Adoption is critical because the settings need to commit their own resources and expect the intervention to "fit" with existing procedures.
Implementation in an efficacy trial is usually accomplished by research staff following a standardized protocol, whereas in an effectiveness trial, regular stciff with many competing demands on their time must implement the intervention. While such staff are also guided by a protocol, adherence is likely to be more variable.' Because they are implemented by research staff, efficacy interventions are often more complex and intensive than effectiveness interventions. Maintenance is usually a nonissue for efficacy trials at the setting level; it is expected that the intervention will cease when final assessments are completed and research staff depart Since effectiveness trials are intended to represent typical setting conditions, it is hoped that the intervention will be maintained, assuming there are positive results.
WHY THE DISCONNECT?
We conclude that the characteristics that cause an intervention to be successful in efficacy research (e.g., intensive, complex, highly standardized) are fundamentally different from, and often at odds with, programs that succeed in population-based effectiveness settings (e.g., having broad appeal, being adaptable for both participants and intervention agents). If this is the case, then the "system" of moving from research to usual service progrtims, to which we have subscribed, may be broken and may need to be substantially modified.
Why does this linear progression of research, which is analogous to the steps used successfully to evaluate emd bring pharmaceuticals to market, seem to fail with behavioral and health promotion research? One contextual factor is that, before trials, pharmaceutical companies invest considerable time and money establishing that the drug affects relevant biological mediators to a much greater extent than behavioral researchers invest in showing that their interventions affect psychosocial mediators. Granted, industry has vastly more resources. But we suggest that key differences also reside in the nature of the interventions.
Standard medical interventions (e.g., drugs or surgery) are presumed to be robust, readily transferable from setting to setting, and to work approximately equally across broad categories of patients. Clinicians exercise discretion about dosage and surgeons vary in experience, but it is still presumed that the pill is the same whoever administers it Medicinal and surgical protocols can be relatively precisely defined, and adherence to them can be more easily monitored relative to behavioral interventions. Behavioral interventions are more difficult to define and standardize in part because of the inherent interactivity with client characteristics, preferences, and behaviors. This is exacerbated when behavioral interventions are delivered by staff whose training and expertise fall outside of behavioral science. In efficacy trials, research st£iff usually bring expertise in behavioral intervention and ensure that it is implemented consistently. This level of quality control and standardization is typically absent among regular health care staff implementing interventions for effectiveness trials.
Tbere are 2 underl}Tng differences between efficacy and effectiveness approaches that we feel are responsible for the current state of affairs. Tbe first is that in an effort to enhance internal validity and control extraneous factors, the tradition in efficacy studies has been to simplify and narrow settings, conditions, participants, and a variety of other factors. There is nothing inherently wrong with this methodological approach, and the tradition of reductionism (e.g., understanding effects by isolating them and removing or controlling other factors) has contributed much to the advancement of science and theory.^' The problem is that usually the longer-range intent is to generalize beyond the narrow conditions of the efficacy trial. In effectiveness trials, an intervention must be robust across a variety of different participants, settings, conditions, and other less controlled factors. Equally important, it must appeal to a broad "defined population" or target audience.
A dassic example of the typical differences between a health care efficacy study and an effectiveness trial concerns subject selection. In a tightly controlled efficacy trial, only highly motivated, homogenous self-selected volunteers who do not have any complications or other comorbid conditions are eligible (to control for potential confounding factors). Then, following success in such an efficacy study, we expect the same intervention to appeal to and be effective in a much broader cross-section of participants, many of whom have comorbid conditions and may not volunteer for treatment
The second key difference between efficacy and effectiveness trials concerns how settings and contextual factors are treated. In efficacy studies, the usual approach is to control variance by restricting the setting to one set of circumstances-for example, one particular clinic (which often includes intervention experts). In contrast, a key characteristic of effectiveness trials is to produce robust effects and to understand variation in outcomes across heterogeneous settings and delivery agents. Therefore, it should not be surprising when the results of an intervention are efficacious under a highly specific set of circumstances but fail to replicate across a vkide variety of settings, conditions, and intervention agents in effectiveness research.
SHALL THE TWAIN EVER MEET?
From the above discussion, it may seem hopeless to expect congruence across findings fi'om efficacy and effectiveness studies. Some might go so far as to suggest, as one reviewer of this manuscript did, that perhaps efficacy studies should be abandoned altogether. We are optimistic, however, that there are solutions to the present disconnect. In brief, we need to embrace and study the complexity of the world, rather than attempting to ignore or reduce it by studying only isolated (and often unrepresentative) situations.''^ What is needed is a "science of larger social units"'''' that takes into account and analyzes the social context(s) in which experiments are conducted. To advance our present state of science, the question that we need to ask of both efficacy and effectiveness studies is "What are the characteristics of interventions that can (a) reach large numbers of people, especially those who can most benefit, (b) he broadly adopted by different settings (worksite, school, health, or community), (c) be consistently implemented by different staff members with moderate levels of training and expertise, and (d) produce replicable and long-lasting effects (and minimal negative impacts) at a reasonable cost?" This suggested focus has important implications. It implies that we need to consider not only individual participants but also the settings within which they reside and receive treatment This move to a multilevel approach is consistent with developments in several fields, and methodologies for how to handle such factors are available. There is not only a rich conceptual history to the study of generalization"*"* and of representative or purposeful sampling,''^'^^ but also statistical methods for handling these contextual factors.''T his comes down to an issue of generalization.^* The prevailing view seems to be that efficacy studies should focus only on interned validity and theoretical process mechanisms, and that issues of external validity should be left until later effectiveness studies. In contrast, we argue that issues of moderating variables (external validity) need to be addressed in both efficacy cind effectiveness studies. Brewer''* conceptualizes such sodal context factors as moderating variables that infiuence the conclusions that can be drawn about the efficacy of an intervention. Moderating variahles (e.g., race/ethnicity, socioeconomic status, type of setting or intervention agent) are relatively stable factors that interact with the intervention or change the effect of the program. Researchers should consider elevating hypotheses related to moderator variables to primary aims.
WHAT CAN BE DONE? DISCUSSION AND RECOMMENDATIONS
It is difficult to change established practice patterns, regardless of whether they be of clinidans, researchers, or funding agendes. It cannot reasonably be expected that many sdentists will quickly discontinue practices in which they have been trained and become comfortable. It is also more efficient, and much more under one's control, to continue to conduct efficacy studies without considering moderating variables or external validity because "the purpose is to study interventions under ideal conditions." However, as illustrated above,, this is only true if one does not intend to generalize one's conclusions beyond the very limited sample and conditions of a given study,'•^' which is hardly ever the case in health promotion research.
There is an increasingly well-documented disparity hetween the large amount of information on efficacy and the very small amount of information on effectiveness and representativeness.^''^^'"' To produce significant improvement in the current state of affairs, changes will be necessary on the part of researchers, funding organizations, joumal reviewers, cind grant review panels. We propose 4 spedfic changes-2 of which focus on researchers, 1 on joumal editors, and 1 on funding organizations. Table 2 outlines how data collection and information about moderating factors, such as participant characteristics (reach) and setting characteristics (adoption), can be incorporated into both efficacy and effectiveness research in a manner appropriate to that phase. Using the RE-AIM framework, we suggest that researchers consider the types of settings, intervention agents, and individuals that they wish their program to be used by when designing and evaluating interventions. During efficacy studies, purposeful or oversampling strategies can be used to include both spedfic end-user groups (e.g., minorities, less educated) and settings of interest A critical concem for broader application-and an integral part of Flay's original description'*-was measurement of potential harmful outcomes. This part of his definition has seldom been addressed, but it needs to be.
Researchers should pay increased attention to moderating factors in both efficaqj and effectiveness research.
Participatory research methods, including developing one's intervention ideas collaboratively with members of the intended audience (individuals, intervention agents, and organization decisionmakers) should not be left for later phases of research but built into efficacy studies. More formal measures of adoption and setting level maintenance may need to wait until later effectiveness studies (Table 2 ), but both qualitative and quantitative "proxy measures" of these factors can and should be addressed in efficacy studies. Such infonnation can lead to better tailoring of interventions to organizational culture in the same way that tailoring of intervention at the individual level has led to increased success."*' ' *^ A final recommendation for both efficacy and effectiveness studies is to include a variety of intervention agents, to describe their backgrounds emd levels of experience/ expertise with regard to the target behavior, and to report on potential differences in implementation and outcomes associated with these differences.'*'' As illustrated in Table 2 , issues pertaining to moderating factors-and eventual translation into practice-are best addressed during the p/anning phases of research. RE-AIM, or other evaluation models,'^'^can be used to help plan and select samples, interventions, settings, and agents in ways that make it more likely that results will be replicated in later studies. 2. Realize that public health impact involves more than just efficacy. Our training and current review criteria all emphasize producing large effect sizes under tightly controlled conditions. To make a real-world impact, several other criteria are also necessary. a. At the individual level, several research groups have proposed that Impact=Reach (R) X Efficacy (E)."^""*^ It is not enough to produce a highly efficadous intervention. To have broad public health impact, an interven- don must also have high reach. To the Impaet=R X E formula, we would add a third eomponent: implementation (I). As diseussed by Basch et al.,'^ a program cannot be effeedve if it is not implemented. Thus, we propose that individual-level Impaet=R x E x I. b. An individual-level foeus is, however, not suffieient An intervention also has to be aeeeptable to and adopted by a variety of intervention settings, and to be implemented relatively consistently by different intervention agents. In other words, the parallel setting or organizational-level impaet formula should be Organizational Impact (01)=Adoption (A) x Implementation (I). Several authors have diseussed issues of nesting and setting factors'''''^ and how to adjust individual-level effects for issues of nonindependenee. However, to otir knowledge, the A x 1=01 formula for estimating the impaet of an intervention across settings has not been diseussed, with the exception of an early related proposal by Kolbe^^ that Impact=Effectiveness x Dissemination x Maintenance. It is important to emphasize that in terms of overall public health effect, adoption and implementation are as important as reach and effieaey, and that we need more emphasis on studies of organizational-and system-level faetors.
3. Include external validity reporting criteria in author guidelines. Within medieine, a widely agreed upon set of criteria for reporting the results of randomized clinical trials has been developed. Known as the CONSORT criteria,^" these reporting standards have been widely adopted by leading medieal journals and have helped to increase the quality of published research. As helpftil as the CONSORT criteria are, they are almost exclusively concerned with issues of internal validity. Only 1 out of 22 reeommendations directly addresses external validity issues^'; in contrast to the other very specific and concrete criteria, it simply states "Generalizability (external validity) of the trial findings" and provides no guidance as to how this issue should be reported.
We propose the following 7 additions to the existing CONSORT criteria, whieh would help greatly to increase awareness of and reporting on extemcil validity. If sueh criteria were widely adopted, it would greatly enhance the quality and information value not only of individual studies but also of evidence-based reviews and meta-analyses. The current state of health promotion research is so biased toward reporting on internal validity issues that it is difficult to draw any eonelusions about generalization. In particular, there has been a serious lack of attention to issues of representativeness, especially at the level of settings and intervention agents.^''^*'^T his becomes even more problematic when the evidence upon which meta-analyses and practice reeommendations are based eonsists largely or solely of effieaey studies of unknown genendizabiUty.
The 7 items that we propose below should apply to both effieacy and effectiveness studies. They would not require a great deal of additional joumal space and are de-scribed below in the same format as existing CONSORT items. These criteria were recently added by the Evidence-Based Behavioral Medicine Committee of the Society of Behavioral Medicine^^ to their recommendations for reporting on behavioral intervention studies.
a. State the target population to which the study intends to generalize. b. Report the rate of exclusions, the participation rate among those eligible, and the representativeness oi participants. c. Report on methods of recruiting study settings, including exclusion rate, pariicipation rate among those approached, and representativeness of settings studied. d. Describe the pariicipation rate and characteristics of those delivering the intervention. State the population of intervention agents that one wotild see eventually implementing the program and how the study interventionists compcire with those who will eventually deliver the intervention. e. Report the extent to which different components of the intervention are delivered (by different intervention agents) as intended in the protocol. f Report the specific time, and costs required to deliver the intervention, g. Report on organizational level of continuance, discontinuance or adaptation in modified form of the intervention once the trial is completed, and individual-level maintenance of results.
We think that such infonnation should be of relevance not only to researchers but also to clinicians, health directors, and decisionmakers responsible for selecting prevention and health promotion programs. In fact, we think that these parties already make implicit tise of these dimensions. Making them explicit should aid reading of the literature and guide more informed program selections. 4 . Increase funding for research focused on moderating variables, external validity, and robustness. The large imbalance between the extent to which health promotion investigations focus on internal validity emd the extent to which they foeus on external validity will not be remedied without substantial ehanges in fiinding priorities. Table 3 lists several reeom- • Fund innovative investigations of ways to enhance reach, adoption, implementation, and maintenance (which have all been de-emphasized relative to efficacy).
• Require standard and comprehensive reporting of exclusions, participation rates, and representativeness of both participants and settings.
• Fund cross-over designs, sequential program changes, replications, multiple baseline, and other designs in addition to randomized controlled trials that can efficiently and practically address key issues in translation.
• Invite programs that investigate and can demonstrate quality implementation and outcomes across a wide range of intervention agents similar to those present in applied settings.
• Require a maintenance/sustainability phase in research projects and implementation of plans to enhance institutionalization once the original research has been completed.
• Fund competitive proposals to investigate long-term effects and sustalnability of initially successful interventions.
• Encourage innovation in intervention design and standardization in reporting on process and outcome measures at both individual and setting/intervention agent levels.
• Request more cost-effectiveness studies and other economic evaluations that are of interest to program administrators and policymakers.
mendations for fiinding organizations that would help correct this imbalance.
These reeommendations would have 2 effeets. The first would be to increase the small number of well-eonducted effectiveness studies now available. The second would be to increase the relevance of efficacy studies for practice by focusing attention on moderating variables and the range of conditions, settings, intervention agents, and partidpants to whieh the results apply. Such refocused funding priorities should also increase tmderstanding of health disparities and help reduce them, since more research would be conducted involving minorities and low-income settings. Finally, fiinding organizations might explicitly have reviewers rate proposals on their likely robustness or potential for widespread application and impact. This could be done by methods described in the Gtiide to Community Preventive Services.'Ĉ
ONCLUSIONS
In summary, at least part of the reason for the slow and uneven translation of research findings into practice in the health promotion sciences is lack of attention to issues of generalization and extemal validity (moderating factors that potentially limit the robustness of interventions). There also needs to be a greater understanding of, and research on, setting-level social contextual faetors.'^'^^'^^ If these issues were addressed in the design and reporting of efficacy as well as effectiveness studies, it would greatly advance the current quality of research Eind our knowledge base. These issues are to a large extent under the control of researchers, reviewers, and fiinding organizations, and we have listed actions that each of these parties can take to facilitate better transfer from efficacy to effectiveness research. •
